 SAN DIEGO, June 22, 2021 PRNewswire -- Halozyme Therapeutics, Inc. NASDAQ: HALO today announced that the European Commission EC has granted the Janssen Pharmaceutical Companies of Johnson Johnson two marketing authorizations for the subcutaneous formulation of daratumumab, known as DARZALEX SC in the European Union. The first authorization is for the use of DARZALEX SC in combination with bortezomib, cyclophosphamide, and dexamethasone VCd for the treatment of adults with newly diagnosed systemic light-chain AL amyloidosis. 